A global Phase 3 pivotal trial of Atumelnant in adults with congenital adrenal hyperplasia
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Atumelnant (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Registrational; Therapeutic Use
- 16 Jan 2025 New trial record